These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38914552)

  • 1. SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer.
    Li K; Shu D; Li H; Lan A; Zhang W; Tan Z; Huang M; Tomasi ML; Jin A; Yu H; Shen M; Liu S
    Cell Death Dis; 2024 Jun; 15(6):444. PubMed ID: 38914552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
    BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
    Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
    Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
    Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
    Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L
    Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.
    Jeong Y; Bae SY; You D; Jung SP; Choi HJ; Kim I; Lee SK; Yu J; Kim SW; Lee JE; Kim S; Nam SJ
    Cell Physiol Biochem; 2019; 53(5):805-819. PubMed ID: 31670920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
    Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
    Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
    Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
    Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
    Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
    Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.
    Yin L; Zhang XT; Bian XW; Guo YM; Wang ZY
    PLoS One; 2014; 9(9):e107369. PubMed ID: 25203051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
    Kwon YS; Nam KS; Kim S
    Biochem Pharmacol; 2021 Aug; 190():114635. PubMed ID: 34058187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
    Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
    Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
    Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MICAL-L2, as an estrogen-responsive gene, is involved in ER-positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway.
    Wen P; Li J; Wen Z; Guo X; Ma G; Hu S; Xu J; Zhao H; Li R; Liu Y; Wang Y; Gao J
    Biochem Pharmacol; 2024 Jul; 225():116256. PubMed ID: 38729448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.